Jubilant HollisterSteir, a subsidiary of Jubilant Pharmova, made the deal with the US government to provide greater capacity for critical vaccine manufacturing. The $149.6m (€140.5m) was issued as part of the American Rescue Plan, a $1.9tn coronavirus rescue package designed to facilitate the US’ recovery from the pandemic.
For its part, Jubilant will provide $43.4m to contribute to the doubling of its injectable filling production capacity at its Spokane, Washington manufacturing facility.
According to the company, the work will provide greater capacity for parenteral products, as well as creating a flexible manufacturing platform to produce different types of vaccine. The site is able to produce live, mRNA, and inactivated/subunit vaccines.
Jubilant offers sterile manufacturing services from the Spokane site from clinical through to commercial liquid and lyophilized vials.
Currently, the two manufacturing complexes present at the site contain two commercial high-speed lines, with the filling process integrated from vial washing through to capping. The facility can also accommodate vials from 2ml through to 100ml, and batch sizes from 2L to 1,500L.
The investment into Jubilant’s manufacturing network will build out its presence in North America. The company already owns four manufacturing facilities in the region, whilst also having two further manufacturing facilities in India, and R&D centers in both locations.
The expansion is expected to be completed by 2025.
Spokane set for investment
This most recent planned expansion arrives after the company had previously announced, in November 2021, that it would build out the Spokane facility with an investment of $92m.
Read Again https://www.biopharma-reporter.com/Article/2022/06/02/Jubilant-wins-US-government-150m-funding-into-vaccine-manufactureBagikan Berita Ini
0 Response to "Jubilant wins US government $150m funding into vaccine manufacture - BioPharma-Reporter.com"
Post a Comment